Fig 1: Assessment of dose for IL-34 treatment in immunotherapy using a mouse modelThe number of CTLA-4 injections in every group was once per week. Mice were divided into four groups depending upon the number of anti-mouse IL-34 antibody doses; Group 1, only CTLA-4 injection; Group 2, one time per week; Group 3, two times per week; Group 4, three times per week (n = 3 per group). Data represent mean ± SEM. Asterisks indicate significance of Group 4 compared to Groups 1, 2, and 3. ∗p < 0.05, Tukey’s multiple comparison test.
Fig 2: Procedure for selecting tissues for patient-derived xenograft (PDX) model establishment(A) Search screen of DNA Link, Inc. online database. Left column shows the setting of the primary site and diagnosis. Middle column shows the state that input the keyword “IL-34” “CD274 (PD-L1)” in the search box. Right column depicts the schematic of the search result.(B) Schematic process of tissue selection for the PDX model.(C) Representative immunohistochemical image of IL-34 (upper, red) and PD-L1 (lower, brown). Scale bar, 20 μm upper panel, 50 μm lower panel.
Fig 3: Procedure for selecting inhibition antibody for IL-34-limitation treatment(A) Steps for selecting anti-human IL-34 antibody as a proper inhibitor in vivo experiment. The peripheral blood covers onto Histopaque®-1077 at first. After centrifugation, four layers (plasma, PBMCs, Histopaque®-1077, RBCs) are observed. PBMCs, peripheral blood mononuclear cells; RBCs, red blood cells.(B) For collecting the isolated PBMCs, aspirate the plasma layer. CD14+ cells from the PBMCs are filtered out using magnetic field and MACS column.(C) CD14+ cells are cultured with recombinant human IL-34 and anti-human IL-34 antibody for 5 days.(D) Representative images of the cultured cells at day 5. The right panel of each group is a magnified image of the left panel. Scale bar, 200 μm left panel, 50 μm right panel.
Supplier Page from BioLegend for Recombinant Human IL-34 (carrier-free)